fluoroquinolones

Summary

Summary: A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.

Top Publications

  1. ncbi Typhoid fever
    Christopher M Parry
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
    N Engl J Med 347:1770-82. 2002
  2. ncbi Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec
    Jacques Pepin
    Department of Microbiology and Infectious Diseases, University of Sherbrooke, Sherbrooke, Quebec, Canada
    Clin Infect Dis 41:1254-60. 2005
  3. ncbi Fluoroquinolones, tuberculosis, and resistance
    Amy Sarah Ginsburg
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet Infect Dis 3:432-42. 2003
  4. ncbi Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments
    Katie L Hopkins
    Antimicrobial Resistance and Molecular Epidemiology Unit, Laboratory of Enteric Pathogens, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5HT, UK
    Int J Antimicrob Agents 25:358-73. 2005
  5. ncbi Efflux-mediated antimicrobial resistance
    Keith Poole
    Department of Microbiology and Immunology, Queen s University, Kingston, ON, Canada
    J Antimicrob Chemother 56:20-51. 2005
  6. ncbi A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use
    Carlene A Muto
    Division of Hospital Epidemiology and Infection Control, University of Pittsburgh Medical Center, Presbyterian Campus, Pittsburgh, Pennsylvania 15213, USA
    Infect Control Hosp Epidemiol 26:273-80. 2005
  7. pmc Interplay in the selection of fluoroquinolone resistance and bacterial fitness
    Linda L Marcusson
    Microbiology Programme, Department of Cell and Molecular Biology, Biomedical Center, Uppsala University, Uppsala, Sweden
    PLoS Pathog 5:e1000541. 2009
  8. pmc The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy
    Christopher M Parry
    Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS Negl Trop Dis 5:e1163. 2011
  9. ncbi Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones
    Syed Hamid Ali
    Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi, Pakistan
    Antivir Ther 12:1-6. 2007
  10. ncbi Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin
    Christine M Sanfilippo
    Bausch and Lomb, Inc, Rochester, N Y, USA
    Chemotherapy 57:363-71. 2011

Detail Information

Publications349 found, 100 shown here

  1. ncbi Typhoid fever
    Christopher M Parry
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
    N Engl J Med 347:1770-82. 2002
  2. ncbi Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec
    Jacques Pepin
    Department of Microbiology and Infectious Diseases, University of Sherbrooke, Sherbrooke, Quebec, Canada
    Clin Infect Dis 41:1254-60. 2005
    ..In 2003, a total of 55% of patients with CDAD at our hospital had received fluoroquinolones in the preceding 2 months...
  3. ncbi Fluoroquinolones, tuberculosis, and resistance
    Amy Sarah Ginsburg
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet Infect Dis 3:432-42. 2003
    Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this ..
  4. ncbi Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments
    Katie L Hopkins
    Antimicrobial Resistance and Molecular Epidemiology Unit, Laboratory of Enteric Pathogens, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5HT, UK
    Int J Antimicrob Agents 25:358-73. 2005
    b>Fluoroquinolones are broad-spectrum antimicrobials highly effective for treatment of a variety of clinical and veterinary infections. Their antibacterial activity is due to inhibition of DNA replication...
  5. ncbi Efflux-mediated antimicrobial resistance
    Keith Poole
    Department of Microbiology and Immunology, Queen s University, Kingston, ON, Canada
    J Antimicrob Chemother 56:20-51. 2005
    ....
  6. ncbi A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use
    Carlene A Muto
    Division of Hospital Epidemiology and Infection Control, University of Pittsburgh Medical Center, Presbyterian Campus, Pittsburgh, Pennsylvania 15213, USA
    Infect Control Hosp Epidemiol 26:273-80. 2005
    b>Fluoroquinolones have not been frequently implicated as a cause of Clostridium difficile outbreaks. Nosocomial C. difficile infections increased from 2.7 to 6.8 cases per 1000 discharges (P < .001)...
  7. pmc Interplay in the selection of fluoroquinolone resistance and bacterial fitness
    Linda L Marcusson
    Microbiology Programme, Department of Cell and Molecular Biology, Biomedical Center, Uppsala University, Uppsala, Sweden
    PLoS Pathog 5:e1000541. 2009
    b>Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate chromosome replication and RNA transcription by regulating chromosome supercoiling...
  8. pmc The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy
    Christopher M Parry
    Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS Negl Trop Dis 5:e1163. 2011
    Infection with Salmonella enterica serovar Typhi (S. Typhi) with reduced susceptibility to fluoroquinolones has been associated with fluoroquinolone treatment failure...
  9. ncbi Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones
    Syed Hamid Ali
    Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi, Pakistan
    Antivir Ther 12:1-6. 2007
    b>Fluoroquinolones represent a potent group of antibiotics that inhibit bacterial DNA replication by targeting the essential bacterial enzymes gyrase and topoisomerase IV...
  10. ncbi Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin
    Christine M Sanfilippo
    Bausch and Lomb, Inc, Rochester, N Y, USA
    Chemotherapy 57:363-71. 2011
    ..MICs) was investigated to better understand why besifloxacin has a higher potency against Staphylococcus aureus when compared to other fluoroquinolones, which was especially pronounced against ciprofloxacin-resistant isolates.
  11. ncbi Fluoroquinolones for the treatment of pulmonary tuberculosis
    Susanne Moadebi
    Vaccine and Pharmacy Services, BC Centre for Disease Control, 655 West 12th Avenue, Vancouver, British Columbia, Canada
    Drugs 67:2077-99. 2007
    ..b>Fluoroquinolones, particularly the newer ones, possess good in vitro (levofloxacin, gatifloxacin, moxifloxacin) and in vivo (..
  12. ncbi Mechanisms of action and resistance of older and newer fluoroquinolones
    D C Hooper
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 2696, USA
    Clin Infect Dis 31:S24-8. 2000
    The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication...
  13. ncbi A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
    R Rustomjee
    Unit for Clinical and Biomedical TB Research, Medical Research Council, Durban, South Africa
    Int J Tuberc Lung Dis 12:128-38. 2008
    Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs).
  14. pmc Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra
    T Kocagoz
    Department of Medicine, University of California, San Francisco 94110, USA
    Antimicrob Agents Chemother 40:1768-74. 1996
    To characterize mechanisms of resistance to fluoroquinolones by Mycobacterium tuberculosis, mutants of strain H37Ra were selected in vitro with ofloxacin...
  15. ncbi High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species
    Dimitry V Viktorov
    Research Institute for Plague Control, Golubinskaya st 7, 400131 Volgograd, Russia
    Trans R Soc Trop Med Hyg 102:S103-10. 2008
    ..pseudomallei, B. mallei and B. thailandensis mutants with increased resistance to fluoroquinolones and cephalosporins were analysed. Resistance to pefloxacin, ofloxacin and ceftazidime in B...
  16. pmc A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system
    Fernanda Maruri
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Antimicrob Chemother 67:819-31. 2012
    ..tuberculosis isolates had mutations in DNA gyrase, but a substantial proportion did not. The proposed consensus numbering system can improve molecular detection of resistance and identification of novel mutations...
  17. ncbi Fluoroquinolone prescribing in the United States: 1995 to 2002
    Jeffrey A Linder
    Division of General Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Am J Med 118:259-68. 2005
    To measure changes in the rate and type of fluoroquinolones prescribed in the United States from 1995 to 2002.
  18. pmc Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study
    John A Crump
    Enteric Diseases Epidemiology Branch, National Center for Zoonotic, Vectorborne, and Enteric Diseases, MS A 38, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 52:1278-84. 2008
    Patients with typhoid fever due to Salmonella enterica serotype Typhi strains for which fluoroquinolones MICs are elevated yet that are classified as susceptible by the current interpretive criteria of the Clinical and Laboratory ..
  19. ncbi Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002
    Ian Morrissey
    GR Micro Ltd, 7 9 William Road, London NW1 3ER, UK
    J Infect 49:109-14. 2004
    ..To determine the identity of European ocular bacterial pathogens and their susceptibility to topical antimicrobial agents...
  20. ncbi Immunomodulatory activities of fluoroquinolones
    A Dalhoff
    Institute for Infection Medicine, University Hospital Schleswig Holstein, Campus Kiel, Brunswiker Str 4, 24105 Kiel, Germany
    Infection 33:55-70. 2005
    A review of published data on the in vitro, ex vivo, in vivo and clinical effects of fluoroquinolones on the synthesis of cytokines is provided. Fluoroquinolones (FQs) were found to affect both cellular and humoral immunity...
  21. ncbi Campylobacter susceptibility to ciprofloxacin and corresponding fluoroquinolone concentrations within the gastrointestinal tracts of chickens
    M B Farnell
    Poultry Production and Product Safety Research Unit, Agricultural Research Service, USDA, Fayetteville, AR 72701, USA
    J Appl Microbiol 99:1043-50. 2005
    ..This study evaluated the relationship between Campylobacter susceptibility and enteric fluoroquinolone concentrations in chickens treated with different doses of enrofloxacin...
  22. ncbi Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis
    Rohit Loomba
    Division of Gastroenterology, University of California at San Diego, La Jolla, California 92093, USA
    Clin Gastroenterol Hepatol 7:487-93. 2009
    ..Our purpose was to determine the beneficial effect of fluoroquinolones as compared with placebo in primary prophylaxis of SBP in high-risk patients with cirrhosis by using meta-..
  23. ncbi Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa
    A Wong-Beringer
    School of Pharmacy, University of Southern California, Los Angeles, California 90033, USA
    Clin Microbiol Infect 14:330-6. 2008
    ..Clinical isolates (n = 45) exhibiting a broad range of susceptibilities to fluoroquinolones, with differing mechanisms of resistance and associated with varying disease sites, were selected for the ..
  24. ncbi Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter spp
    Sophie Payot
    Institut National de la Recherche Agronomique, UR086 BioAgresseurs, santé, Environnement, Nouzilly, France
    Microbes Infect 8:1967-71. 2006
    ..of human Campylobacter infections is increasing worldwide, as well as the proportion of isolates resistant to fluoroquinolones and/or macrolides, the drugs of choice to treat campylobacteriosis...
  25. ncbi Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
    Dennis Falzon
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:156-68. 2013
    ..The analysis assessed the impact of additional resistance to fluoroquinolones and/or second-line injectable drugs on treatment outcome...
  26. pmc Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation
    Steven Gabardi
    Department of Transplant Surgery, Center for for Clinical Investigation, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Clin J Am Soc Nephrol 5:1298-304. 2010
    ..Case reports have evaluated treatment options for BK virus, but no controlled studies have assessed prophylactic therapies. Fluoroquinolone antibiotics were studied for prevention of BK viremia after renal transplantation...
  27. pmc New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations
    Seidu Malik
    Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 7:e39754. 2012
    ..or clinical isolates harboring T80A, T80A+A90G, A90G, G247S and A384V gyrA mutations were susceptible to all fluoroquinolones tested...
  28. pmc Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever
    Kanika Deshpande Koirala
    Oxford University Clinical Research Unit Patan Academy of Health Sciences, Kathmandu, Nepal
    Antimicrob Agents Chemother 56:2761-2. 2012
    As a consequence of multidrug resistance, clinicians are highly dependent on fluoroquinolones for treating the serious systemic infection typhoid fever...
  29. pmc Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones
    Louis B Rice
    Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA
    Mayo Clin Proc 87:198-208. 2012
    ..classes for which resistance has become a major problem include the β-lactams, the glycopeptides, and the fluoroquinolones. In gram-positive bacteria, β-lactam resistance most commonly results from expression of intrinsic low-..
  30. pmc Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study
    Daniel P O'Brien
    Department of Infectious Diseases, Barwon Health, Geelong, Australia
    PLoS Negl Trop Dis 6:e1473. 2012
    ..We describe outcomes and tolerability of fluoroquinolone-containing antibiotic regimens for Mycobacterium ulcerans in south-eastern Australia...
  31. ncbi Molecular and physiological characterization of fluoroquinolone resistance in relation to uropathogenicity among Escherichia coli isolates isolated from Wenyu River, China
    Jianxian Sun
    College of Urban and Environmental Sciences, Peking University, Beijing 100871, China
    Chemosphere 87:37-42. 2012
    ..925, 1° of freedom, p<0.001) indicating that fluoroquinolone-resistant E. coli would pose a potential risk. A similar distribution was also found in isolates resistant to GAT (χ(2)=7.843, 1° of freedom, p=0.0079)...
  32. pmc Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections
    Patricia Komp Lindgren
    Department of Cell and Molecular Biology, Microbiology Programme, Biomedical Center, Uppsala University, S 751 24 Uppsala, Sweden
    Antimicrob Agents Chemother 47:3222-32. 2003
    ..This correlation suggests that an increased general mutation rate may play a significant role in the development of high-level resistance to fluoroquinolones by increasing the rate of accumulation of rare new mutations.
  33. ncbi PatA and PatB form a functional heterodimeric ABC multidrug efflux transporter responsible for the resistance of Streptococcus pneumoniae to fluoroquinolones
    Emilie Boncoeur
    Universite Joseph Fourier Grenoble 1, Institut de Biologie Structurale, Grenoble, France
    Biochemistry 51:7755-65. 2012
    ..e., ethidium bromide or fluoroquinolones, than the wild-type R6 strain...
  34. ncbi Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance
    Melissa Viray
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Infect Control Hosp Epidemiol 26:56-62. 2005
    ..Longitudinal trends in antibiotic resistance in LTCFs have not been well described...
  35. ncbi Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002
    Winfried V Kern
    Center for Infectious Diseases and Travel Medicine, Department of Medicine, Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    J Antimicrob Chemother 55:57-60. 2005
    ..To compare rates of in vitro fluoroquinolone resistance of bacterial isolates obtained from inpatients of two haematology-oncology services with high and low fluoroquinolone consumption...
  36. pmc Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment
    Deborah J Griggs
    Antimicrobial Agents Research Group, Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Antimicrob Agents Chemother 49:699-707. 2005
    ..Most ciprofloxacin-resistant isolates had the GyrA substitution Thr-86-->Ile. Resistant isolates were isolated from the feces of some flocks up to the point of slaughter, which may have consequences for public health...
  37. pmc Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones
    Christopher M Parry
    The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam
    Antimicrob Agents Chemother 54:5201-8. 2010
    ..Screening for nalidixic acid resistance or ciprofloxacin and ofloxacin disk inhibition zone are suitable for detecting S. Typhi isolates with reduced fluoroquinolone susceptibility...
  38. pmc Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay
    Soumitesh Chakravorty
    Division of Infectious Disease, Department of Medicine and the Ruy V Lourenço Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Newark, NJ 07103, USA
    J Clin Microbiol 49:932-40. 2011
    b>Fluoroquinolones (FQ) are important second-line drugs to treat tuberculosis; however, FQ resistance is an emerging problem...
  39. pmc Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 47:1867-74. 2003
    ..9 to 11.1% over the 5 years. For the fluoroquinolones, the order of activity based on the MICs at which 50% of isolates are inhibited (MIC(50)s) and the MIC(90)s ..
  40. pmc Commonality among fluoroquinolone-resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia
    Joanne L Platell
    School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia
    Antimicrob Agents Chemother 55:3782-7. 2011
    ....
  41. ncbi Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes
    Francoise Van Bambeke
    Unité de pharmacologie cellulaire et moléculaire and Centre de Pharmacie Clinique, Louvain Drug Research Institute, Universite Catholique de Louvain, Brussels, Belgium
    Drug Saf 32:359-78. 2009
    ..In this review, we critically examine its safety profile in comparison with other fluoroquinolones and other antibacterial classes sharing similar indications...
  42. pmc Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings
    I Kontsevaya
    Health Protection Agency National Mycobacterium Reference Laboratory and Clinical and HIV Group, Institute for Cell and Molecular Sciences, Barts and the London Medical School, Queen Mary, University of London, 2 Newark Street, London E12AT, United Kingdom
    J Clin Microbiol 49:2832-7. 2011
    ..Rapid diagnosis of resistance to fluoroquinolones (FQs) using molecular assays is essential for the implementation of appropriate drug regimens and prevention ..
  43. pmc DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis
    Alix Pantel
    UPMC Universite Paris 06, ER5, EA 1541, Laboratoire de Bacteriologie Hygiene, F 75005 Paris, France
    Antimicrob Agents Chemother 55:4524-9. 2011
    ..Therefore, the use of FQ in the treatment of tuberculosis (TB) patients should not be ruled out only on the basis of the presence of mutations in gyrB...
  44. pmc Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum
    Josep M Sierra
    Department of Microbiology, School of Medicine, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Antimicrob Agents Chemother 49:1714-9. 2005
    ..amycolatum. Moreover, a PCR-RFLP-NcoI of the gyrA gene was developed to distinguish between C. amycolatum and C. striatum species...
  45. ncbi Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid
    I Escribano
    Section of Microbiology, Hospital General Universitario de Elche, Universidad Miguel Hernandez, Elche, Spain
    Chemotherapy 53:397-401. 2007
    Our aim was to study the influence of efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.
  46. pmc Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007
    Kyungwon Lee
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seodaemun gu, Seoul, Korea
    Yonsei Med J 51:901-11. 2010
    ..We analyzed antimicrobial resistance data generated by Korean Hospitals and by a commercial laboratory in 2005 and 2007...
  47. ncbi Clostridium difficile and fluoroquinolones: is there a link?
    Karl Weiss
    Department of Infectious Diseases and Microbiology, Maisonneuve Rosemont Hospital, University of Montreal, 5415 L Assomption, Montreal, Quebec H1T 2M4, Canada
    Int J Antimicrob Agents 33:S29-32. 2009
    ..The arrival of a new, more virulent strain coincided with the introduction of several new respiratory fluoroquinolones, and several studies have reported a potential link between the use of fluoroquinolones and the occurrence of ..
  48. ncbi In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
    J C Rodriguez
    Section of Microbiology, Hospital General Universitario de Elche, Universidad Miguel Hernandez, 03202 Elche Alicante, Spain
    Int J Antimicrob Agents 17:229-31. 2001
    ..The MIC(90) for ofloxacin was 2 mg/l and for ciprofloxacin 4 mg/l. Further studies should be made to determine the role played by these compounds in the treatment of tuberculosis...
  49. pmc In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone
    Brian J Morrow
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 54:1955-64. 2010
    ..and Escherichia coli were indicative of a lower potential for resistance development than that for current fluoroquinolones. In conclusion, JNJ-Q2 exhibits a range of antibacterial activities in vitro that is supportive of its ..
  50. pmc Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis
    Karen R Jacobson
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:6-14. 2010
    ..TB strains are, by definition, resistant to the most potent second-line options: the injectable agents and fluoroquinolones. We conducted a meta-analysis to assess XDR TB treatment outcomes and to identify therapeutic approaches ..
  51. ncbi Mechanisms of action of antimicrobials: focus on fluoroquinolones
    D C Hooper
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Clin Infect Dis 32:S9-S15. 2001
    ..The fluoroquinolones are the only direct inhibitors of DNA synthesis; by binding to the enzyme-DNA complex, they stabilize DNA ..
  52. pmc Salmonellosis in Lagos, Nigeria: incidence of Plasmodium falciparum-associated co-infection, patterns of antimicrobial resistance, and emergence of reduced susceptibility to fluoroquinolones
    Kabir O Akinyemi
    Department of Microbiology, Lagos State University, Ojo PMB 1087, Apapa, Lagos, Nigeria
    J Health Popul Nutr 25:351-8. 2007
    ..resistance in Salmonella-associated diseases, by verifying possible emergence of reduced susceptibility to fluoroquinolones in Salmonella isolates and determining the incidence of Plasmodium falciparum-associated co-infection with ..
  53. pmc Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model
    Julien Poissy
    Laboratoire de Bacteriologie Hygiene, Faculte de Medecine, Pierre et Marie Curie Université Paris, 91 Boulevard de l Hopital, Paris Cedex 13, France
    Antimicrob Agents Chemother 54:4765-71. 2010
    ..of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide...
  54. pmc Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates
    J Engberg
    Department of Gastrointestinal Infections, Division of Diagnostics, Statens Serum Institut, Artillerivej 5, DK 2300 Copenhagen S, Denmark
    Emerg Infect Dis 7:24-34. 2001
    ..should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.
  55. ncbi Moxifloxacin
    J A Balfour
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:363-73; discussion 374. 1999
    ..In common with other fluoroquinolones, moxifloxacin attains good penetration into respiratory tissues and fluids and its bioavailability is ..
  56. ncbi In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis
    J C Rodriguez
    Section of Microbiology, Hospital General Universitario de Elche, Universidad Miguel Hernandez, 03202 Elche, Alicante, Spain
    Int J Antimicrob Agents 20:464-7. 2002
    ..Three strains were resistant to isoniazid and to the fluoroquinolones, which suggested the existence of mechanisms of resistance not yet described...
  57. pmc Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones
    Stéphanie Arsène
    CHU de Caen, Service de Microbiologie, Avenue Cote de Nacre, 14033 Caen Cedex, France
    Antimicrob Agents Chemother 51:3254-8. 2007
    b>Fluoroquinolones are poorly active against enterococci. Recently, plasmid-borne resistance to fluoroquinolones due to the qnr gene was reported in members of the Enterobacteriaceae family...
  58. ncbi Fluoroquinolones: a new treatment for tuberculosis?
    S H Gillespie
    Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK
    Int J Tuberc Lung Dis 2:265-71. 1998
    The fluoroquinolones have secured an important place in the management of bacterial infection, they are well absorbed orally, are found in respiratory secretions in higher concentrations than in serum and are concentrated inside ..
  59. ncbi Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years
    Michael K Jensen
    Department of Pharmacy Services, Moran Eye Center, University of Utah Hospital, 65 North Medical Drive, Salt Lake City, UT 84132, USA
    J Cataract Refract Surg 34:1460-7. 2008
    To determine differences in endophthalmitis rates with prophylactic use of third- versus fourth-generation fluoroquinolones in cataract surgery.
  60. ncbi Association of antimicrobial resistance in Campylobacter isolated from food-producing animals with antimicrobial use on farms
    Tetsuo Asai
    National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries, Tokyo 185 8511, Japan
    Jpn J Infect Dis 60:290-4. 2007
    ..Tetracyclines and fluoroquinolones were used for therapeutic purposes on 107 and 21 farms, respectively. Oxytetracycline-resistant C...
  61. pmc Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB
    Andrea von Groll
    Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium
    Antimicrob Agents Chemother 53:4498-500. 2009
    ..Forty strains shared the same resistance results for the three fluoroquinolones. However, one strain, with an Asn-533 --> Thr mutation in gyrB, was susceptible to ofloxacin but resistant ..
  62. pmc Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients
    Stephen G Weber
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Emerg Infect Dis 9:1415-22. 2003
    ..4; p <0.0001; ciprofloxacin OR 2.5; p = 0.005) but not MSSA. Exposure to levofloxacin or ciprofloxacin is a significant risk factor for the isolation of MRSA, but not MSSA...
  63. pmc gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
    L M Weigel
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 42:2661-7. 1998
    ..A single point mutation in gyrA has been shown to reduce susceptibility to fluoroquinolones. To determine the extent of gyrA mutations associated with FQ-R in enteric bacteria, one set of ..
  64. pmc Quinolone-resistant Campylobacter infections: risk factors and clinical consequences
    Jørgen Engberg
    Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark
    Emerg Infect Dis 10:1056-63. 2004
    ..jejuni infections. An association between treatment with a fluoroquinolone before stool-specimen collection and having a quinolone-resistant C. jejuni infection was not observed...
  65. pmc Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
    Wolfgang Haas
    Bausch and Lomb, Inc, 1400 N Goodman St, Rochester, NY 14609, USA
    Antimicrob Agents Chemother 53:3552-60. 2009
    ..potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens...
  66. ncbi Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003
    Tsi Shu Huang
    Section of Microbiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
    J Antimicrob Chemother 56:1058-62. 2005
    b>Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB)...
  67. pmc Evolutionary history of Salmonella typhi
    Philippe Roumagnac
    Max Planck Institut für Infektionsbiologie, Department of Molecular Biology, Chariteplatz 1, 10117 Berlin, Germany
    Science 314:1301-4. 2006
    ..In contrast, clinical use of fluoroquinolones has yielded at least 15 independent gyrA mutations within a decade and stimulated clonal expansion of ..
  68. pmc Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae
    Somesh Baranwal
    Department of Chemistry, Bose Institute, 93 1 Acharya Prafulla Chandra Road, Kolkata 700009, India
    Antimicrob Agents Chemother 46:2676-8. 2002
    ..In this study, we demonstrate that, in addition to mutations detected in the target genes gyrA and parC, proton motive force-dependent efflux is involved in quinolone resistance in clinical isolates of V. cholerae...
  69. ncbi Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients
    Anat Gafter-Gvili
    Rabin Medical Center, Petah Tiqva, Israel
    Ann Intern Med 142:979-95. 2005
    ..Trials have shown the efficacy of antibiotic prophylaxis in decreasing the incidence of bacterial infections but not in reducing mortality rates...
  70. ncbi Solid-phase extraction of fluoroquinolones from aqueous samples using a water-compatible stochiometrically imprinted polymer
    Elena Benito-Peña
    Department of Analytical Chemistry, Faculty of Chemistry, Universidad Complutense de Madrid, E 28040 Madrid, Spain
    J Chromatogr A 1208:62-70. 2008
    ..The results demonstrate the applicability of the optimized method for the selective extraction of fluoroquinolones in environmental water samples at the ngL(-1) level.
  71. ncbi Oral fluoroquinolones and the risk of retinal detachment
    Mahyar Etminan
    Therapeutic Evaluation Unit, Child and Family Research Institute of British Columbia, Vancouver, Canada
    JAMA 307:1414-9. 2012
    b>Fluoroquinolones are commonly prescribed classes of antibiotics. Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, particularly retinal detachment, has not been performed.
  72. ncbi Environmental exposure assessment of fluoroquinolone antibacterial agents from sewage to soil
    Eva M Golet
    Swiss Federal Institute for Environmental Science and Technology EAWAG, CH 8600 Dubendorf, Switzerland
    Environ Sci Technol 37:3243-9. 2003
    ..Field experiments of sludge-application to agricultural land confirmed the long-term persistence of trace amounts of FQs in sludge-treated soils and indicated a limited mobility of FQs into the subsoil...
  73. ncbi Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion
    Gracia Merino
    Department of Physiology, Faculty of Veterinary Medicine, University of Leon, Campus de Vegazana, 24071 Leon, Spain
    Drug Metab Dispos 34:690-5. 2006
    ..We conclude that Bcrp1 is one of the determinants for the bioavailability of fluoroquinolones and their secretion into the milk.
  74. ncbi Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro
    R Anderson
    Medical Research Council MRC Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, and Tshwane Academic Division of the National Health Laboratory Service, South Africa
    J Antimicrob Chemother 60:1155-8. 2007
    ....
  75. pmc A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children
    Ha Vinh
    The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS Negl Trop Dis 5:e1264. 2011
    ..Resistance to nalidixic acid is a marker of reduced susceptibility to older generation fluoroquinolones, such as ciprofloxacin...
  76. ncbi Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones
    Louis D Saravolatz
    Department of Medicine, St John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan 48236, USA
    Clin Infect Dis 37:1210-5. 2003
    Gatifloxacin, gemifloxacin, and moxifloxacin are the newest fluoroquinolones and show excellent in vitro activity against a wide variety of respiratory tract pathogens, many gram-negative aerobic organisms, and Bacteroides fragilis...
  77. pmc Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates
    Sonia K Morgan-Linnell
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030 3411, USA
    Antimicrob Agents Chemother 53:235-41. 2009
    ..Increased AcrA correlated with nonsusceptibility to the fluoroquinolones but did not correlate with nonsusceptibility to any other antimicrobial agents reported from hospital ..
  78. pmc Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates
    Augustine F B Cheng
    Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China
    Antimicrob Agents Chemother 48:596-601. 2004
    ..and were found to correlate strongly with the in vitro susceptibilities of the mutant strains to six fluoroquinolones (ofloxacin, levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, and sitafloxacin)...
  79. pmc Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis
    Yan Feng
    Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People s Republic of China
    PLoS ONE 8:e55292. 2013
    ..to synthesize the latest data on the diagnostic accuracy of GenoType MTBDRsl in detecting drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol, in comparison with the phenotypic drug susceptibility test.
  80. ncbi Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure
    Meiguan Yan
    Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
    J Antimicrob Chemother 58:1154-9. 2006
    ..The objective of this study was to determine the contribution of the CmeABC efflux pump to the emergence of fluoroquinolone (FQ)-resistant mutants in Campylobacter jejuni under various levels of selection pressure...
  81. ncbi Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection
    Francesco Scaglione
    University of Milan, Department of Pharmacology, Chemotherapy and Toxicology, Faculty of Medicine, Via Vanvitelli 32, 20129, Milan, Italy
    Expert Rev Anti Infect Ther 4:479-90. 2006
    ..This review will analyze the typical patterns of antimicrobial activity and the corresponding PK/PD parameters, with a special focus on a PK/PD dosing approach with the most commonly utilized antimicrobial agent classes...
  82. ncbi Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea
    J Y Kim
    Division of Enteric Bacterial Infections, Center for Infectious Disease, National Institute of Health and Institute of Global Environmental and Department of Biology, Kyung Hee University, Seoul, Korea
    Clin Microbiol Infect 14:760-5. 2008
    Among 5938 clinical Shigella spp. isolates, two S. flexneri strains were isolated as those resistant to fluoroquinolones based on the MICs of the following antibiotics: ciprofloxacin, norfloxacin, ofloxacin, sparfloxacin and levofloxacin...
  83. ncbi Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae
    Farid El Garch
    Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Universite Catholique de Louvain, Brussels, Belgium
    J Antimicrob Chemother 65:2076-82. 2010
    Active efflux is a common mechanism of resistance to fluoroquinolones in Streptococcus pneumoniae...
  84. pmc The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance
    Vincent H Tam
    Emerging Infections and Host Defense Laboratory, Ordway Research Institute, Albany, NY, USA
    Antimicrob Agents Chemother 51:744-7. 2007
    ..Different targets for the area under the concentration-time curve over 24 h/MIC ratio were required for different bacteria...
  85. ncbi Adverse reactions to fluoroquinolones. an overview on mechanistic aspects
    A De Sarro
    Istituto di Farmacologia, Facolta di Medicina e Chirurgia, Universita di Messina, Policlinico Universitario, Via Consolare Valeria, Messina, 98125, Italia
    Curr Med Chem 8:371-84. 2001
    ..In this article we review the toxicity of fluoroquinolones, including the newer derivatives such levofloxacin, sparfloxacin, graepafloxacin and the 7-azabicyclo ..
  86. pmc Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens
    B Charleston
    Institute for Animal Health, Compton, Newbury, Berkshire, United Kingdom Bryan
    Antimicrob Agents Chemother 42:83-7. 1998
    ..This experiment showed that continuous dosing and pulsed dosing are clinically equivalent. However, for all fluoroquinolones studied, there was a trend for the continuously mediated birds to have lower mortality and less severe ..
  87. ncbi Fluoroquinolones: structure and target sites
    P G Higgins
    Institute for Medical Microbiology and Virology, Universitatsklinikum Dusseldorf, Universitatsstrasse 1, Geb 22 21, 40225 Dusseldorf, Germany
    Curr Drug Targets 4:181-90. 2003
    ..undergone structural modifications, in particular the addition of a fluorine at position 6, to produce the fluoroquinolones. This has seen their potency and pharmakokinetic profile greatly increase...
  88. ncbi Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations
    Pierre Robert Smeesters
    Laboratoire de Génétique et Physiologie Bactérienne, Institut de Biologie et de Médecine Moléculaires IBMM, Faculte des Sciences, Universite Libre de Bruxelles, 12 rue des Professeurs Jeener et Brachet, 6041 Gosselies, Belgium
    Int J Antimicrob Agents 34:44-9. 2009
    Clonal emergence of group A streptococci (GAS) with reduced susceptibility to fluoroquinolones (FQs) has been increasingly reported...
  89. ncbi Fluoroquinolone resistance in campylobacter
    James L Smith
    Microbial Food Safety Unit, Eastern Regional Research Center, Agricultural Research Service, U S Department of Agriculture, 600 East Mermaid Lane, Wyndmoor, Pennsylvania 19038 8598, USA
    J Food Prot 73:1141-52. 2010
    ..b>Fluoroquinolones inhibit the growth of Campylobacter and other microorganisms by binding to bacterial DNA gyrase and DNA ..
  90. ncbi In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents
    Tao Lu
    Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    J Antimicrob Chemother 52:1025-8. 2003
    To examine the effect of first-line and second-line anti-tuberculosis agents on the ability of fluoroquinolones to kill mycobacteria.
  91. pmc GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples
    A Lacoma
    Servei de Microbiologiaa and Servei de Pneumologia, b Hospital Universitari Germans Trias i Pujol, Institut d Investigacio Germans Trias i Pujol, Universitat Autònoma deBarcelona, Badalona, Spain
    J Clin Microbiol 50:30-6. 2012
    ..the GenoType MTBDRsl assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to fluoroquinolones (FLQ), injectable second-line antibiotics [kanamycin (KM) and capreomycin (CM)], and ethambutol (EMB) in ..
  92. ncbi Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000
    Marcus J Zervos
    William Beaumont Hospital, Royal Oak, Michigan 48073, USA
    Clin Infect Dis 37:1643-8. 2003
    ..examined the relationship between fluoroquinolone use and the susceptibilities of 11 bacterial pathogens to fluoroquinolones in 10 US teaching hospitals from 1991 through 2000...
  93. ncbi Safety considerations of fluoroquinolones in the elderly: an update
    Ralf Stahlmann
    Institute of Clinical Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Drugs Aging 27:193-209. 2010
    The fluoroquinolones ciprofloxacin, levofloxacin, moxifloxacin and gemifloxacin are widely used for the treatment of various types of bacterial infections...
  94. ncbi QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications
    Alexandros Briasoulis
    Department of Medicine, St Luke s Roosevelt Hospital Center, 515 West 59th Street, New York, NY 10019, USA
    Cardiology 120:103-10. 2011
    Although very useful agents, fluoroquinolones are associated with a number of adverse events, some with considerable clinical significance...
  95. ncbi Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae
    L Drago
    Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy
    J Antimicrob Chemother 66:845-9. 2011
    ..mechanisms of resistance to the main drugs for the treatment of pneumonia, such as β-lactams, macrolides and fluoroquinolones. The present study aimed to compare the antipneumococcal activity of combinations of respiratory ..
  96. pmc Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor
    Matthew W Vetting
    Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Biol Chem 286:25265-73. 2011
    QnrB1 is a plasmid-encoded pentapeptide repeat protein (PRP) that confers a moderate degree of resistance to fluoroquinolones. Its gene was cloned into an expression vector with an N-terminal polyhistidine tag, and the protein was ..
  97. ncbi Selection and characterization of fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin
    Sophie Payot
    UR86 de Pathologie Aviaire et Parasitologie, Institut National de la Recherche Agronomique, 37380 Nouzilly, France
    Microb Drug Resist 8:335-43. 2002
    ..Further steps of selection increased the MICs of fluoroquinolones but did not result in a multiple antibiotic resistance phenotype...
  98. pmc Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
    Stephanie Matrat
    Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:745-7. 2008
    ..We demonstrated that the gyrA mutations leading to G89C or A91V confer fluoroquinolone resistance whereas the gyrB mutation leading to D205N does not...
  99. pmc Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice
    A Bentoucha
    , , Paris, France
    Antimicrob Agents Chemother 45:3109-12. 2001
    ..The RIF+AMK combination and possibly RIF+STR warrant further study for the treatment of M. ulcerans infection in humans...
  100. pmc Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018
    Patrizia Spigaglia
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    J Clin Microbiol 48:2892-6. 2010
    Recent evidence strongly suggests an association between the use of fluoroquinolones and Clostridium difficile infection (CDI)...
  101. pmc Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise
    Octavie Lunguya
    National Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo
    PLoS Negl Trop Dis 6:e1921. 2012
    ..Although increased use of fluoroquinolones is associated with spread of resistance, Salmonella Typhi with decreased ciprofloxacin susceptibility (DCS) ..

Research Grants65

  1. Molecular Basis of E. coli Adhesins in Bladder Disorders
    Scott J Hultgren; Fiscal Year: 2013
    ..resistance to first-line empiric therapie such as trimethoprim-sulfamethoxazole and the undesirable use of fluoroquinolones for empiric treatment of UTI. Catheter-associated UTI (CAUTI) further exacerbates this problem...
  2. Genetic Manipulation of Unreaplasma spp. Infecting Humans using Synthetic Genomic
    JOHN IRVIN GLASS; Fiscal Year: 2013
    ..infections resistant to antibiotics are increasingly common and the best drugs for ureaplasma treatment, fluoroquinolones and tetracyclines, are not recommended for pregnant women or children...
  3. Compounds to treat Helicobacter pylori infection
    Kenneth Coleman; Fiscal Year: 2013
    ..However, the last class of antibiotics acting against Gram negative species, the fluoroquinolones, was discovered 50 years ago...
  4. HTS assay development targeting Yersinia pestis topoisomerase I
    Yuk Ching Tse-Dinh; Fiscal Year: 2011
    ..of bacterial topoisomerase I DNA cleavage products should be effective bactericidal agents, similar to fluoroquinolones that target bacterial type IIA topoisomerases, but would not be affected by the prevalent fluoroquinolone ..
  5. Ciprofloxacin enhances DNA repair capacity after radiation combined injury
    JULIANN GONG KIANG; Fiscal Year: 2012
    This application addresses a major gap for medical treatment of radiation combined injuries (CI). Fluoroquinolones, like ciprofloxacin (CIP), are generally well-tolerated and commonly used for treating infections in the general population...
  6. Narrow-spectrum Agents Acting against Helicobacter pylori
    Kenneth Coleman; Fiscal Year: 2013
    ..a new therapeutic are formidable - the last class of antibiotics acting against Gram negative species, the fluoroquinolones, was introduced 40 years ago...
  7. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO
    John D Sheppard; Fiscal Year: 2010
    ..This can most readily be seen in the emergence of antimicrobial resistance to second and third generation fluoroquinolones requiring the subsequent development and application of fourth generation fluoroquinolones...
  8. Molecular bssis of mef-mediated antibiotic resistance in Streptococcus pneumoniae
    David S Stephens; Fiscal Year: 2010
    ..g., trimethoprim-sulfa, fluoroquinolones, that induce an SOS stress response in pneumococci...
  9. Novel fluoroquinolones for killing dormant Mycobacterium tuberculosis
    Xilin Zhao; Fiscal Year: 2013
    ..Our goal is to obtain new fluoroquinolones that rapidly kill non-growing M. tuberculosis and would thereby reduce treatment time radically...
  10. HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY
    George Wright; Fiscal Year: 2009
    ..pol IIIC inhibitors, and have broader activity against clinical isolates of Gram-positive bacteria than the fluoroquinolones, both in vitro and in vivo...
  11. Molecular Targets in Peptidoglycan Synthesis
    Christopher Davies; Fiscal Year: 2013
    ..has severely limited treatment options for gonococcal infections and, after the recent withdrawal of fluoroquinolones, the expanded-spectrum cephalosporin ceftriaxone is now the only single-dose treatment recommended by the CDC ..
  12. Pseudomonas aeruginosa Adaptation During Early CF Airway Infection and Treatment
    Lucas R Hoffman; Fiscal Year: 2012
    ..to the three classes of antibiotic used most often in CF therapy: [unreadable]lactams, aminoglycosides, and fluoroquinolones. Conversely, LasR mutants are more susceptible in vitro to at least two classes of metabolic inhibitors, ..
  13. MepRA, A Substrate-Responsive Repressor-MATE MDR Efflux Pump Tandem in S. aureus
    GLENN WILLIAM KAATZ; Fiscal Year: 2013
    ..substrates for MATE pumps include mono- and bivalent organic cations such as biocides and disinfectants, fluoroquinolones, and anticancer agents. Acquisition of MDR S...
  14. Epidemiology of Community-Associated, ESBL-Producing Escherichia coli
    Yohei Doi; Fiscal Year: 2010
    ..These organisms are not only resistant to most beta-lactams but also fluoroquinolones and aminoglycosides. ESBL producers have typically been regarded as a problem confined to hospitals...
  15. Dynamics and regulation of sister chromosome cohesion in E. coli.
    David Bates; Fiscal Year: 2013
    ..unknown roles of Topo IV protein, target of the most highly prescribed class of antibiotics in the world, the fluoroquinolones. (iii) We also predict that it will illuminate parallel cohesion mechanisms that occur in eukaryotes, and ..
  16. Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
    C Robert Horsburgh; Fiscal Year: 2010
    ..The fluoroquinolones (FQ) are the most active class of antimycobacterial agents currently available for use in patients with MDR-..
  17. Emerging Macrolide Resistance in Mycoplasma Pneumoniae
    THOMAS PRESCOTT ATKINSON; Fiscal Year: 2010
    ..At present three classes of drugs are used to treat M. pneumoniae infections: macrolides, tetracyclines, and fluoroquinolones. Of these only macrolides are generally considered acceptable for use in children under the age of 8 years...
  18. LpxC inhibitors as a novel class of antibiotics against N. gonorrhoeae
    Pei Zhou; Fiscal Year: 2013
    ..all of the antibiotics that have been used to treat infections, including penicillin, tetracycline, and fluoroquinolones. The minimum inhibitory concentrations (MICs) of the sole antibiotic recommended for treatment of gonococcal ..
  19. PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN
    ANNEKE CATHARINA HESSELING; Fiscal Year: 2013
    ..The most frequently used second-line anti-TB drugs in children in the PIs'setting are ethionamide, fluoroquinolones, amikacin and terizidone...
  20. Rapid Diagnostic Testing of Urinary Tract Infections
    RONALD J RIEDER; Fiscal Year: 2010
    ..Already, authorities advise the use of significantly more expensive fluoroquinolones as a first line treatment for uncomplicated UTIs when the prevailing rate of antibiotic resistance in the ..
  21. Mechanisms of antibiotic action in Neisseria gonorrhoeae.
    Robert A Nicholas; Fiscal Year: 2010
    ..and tetracycline were once the antibiotics of choice but are no longer effective, and resistance to fluoroquinolones is rapidly increasing...
  22. COMBATTING QUINOLONE ANTIMICROBIAL RESISTANCE
    ELIZABETH LYNN ZECHIEDRICH; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Fluoroquinolones are the most frequently prescribed antimicrobial agents in the United States...
  23. Impact of Effective Chemotherapy on Transmission of Drug Resistant Tuberculosis
    MARTHA LOUIZA VAN DER WALT; Fiscal Year: 2013
    ..MDR treatment will rapidly and profoundly stop transmission, but that in the absence of susceptibility to fluoroquinolones, transmission will be less well inhibited by the remaining drugs available for the tailored regimens in use ..
  24. Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
    C Robert Horsburgh; Fiscal Year: 2013
    ..b>Fluoroquinolones (FQ) are an essential part of regimens for the treatment of MDR-TB;substantially better outcomes have ..
  25. Detection of Antibiotic Resistance Genes in Bacterial Agents of Hospital-Acquired
    Andrew Levin; Fiscal Year: 2009
    ..and genetic determinants of antibiotic resistance, including resistance to [unreadable]-lactams and fluoroquinolones in Gram-negative bacteria, and to methicillin and vancomycin in Gram-positive bacteria...
  26. Predicting the risk of C. difficile infection to improve fluoroquinolone use
    Jennifer L Kuntz; Fiscal Year: 2011
    ..The proposed research will focus on the risk of infection following the use of fluoroquinolones, an antimicrobial class associated with CDI outbreaks...
  27. Development, Implementation and Evaluation of Novel Strategies to Reduce Inapprop
    CURTIS DONSKEY; Fiscal Year: 2010
    ..combining the intervention for prevention and management of UTI with an intervention to decrease overuse of fluoroquinolones for other indications will maximize the potential to significantly reduce selective pressure exerted by these ..
  28. Ciprofloxacin enhances DNA repair capacity after radiation combined injury
    JULIANN KIANG; Fiscal Year: 2009
    This application addresses a major gap for medical treatment of radiation combined injuries (CI). Fluoroquinolones, like ciprofloxacin (CIP), are generally well-tolerated and commonly used for treating infections in the general ..
  29. Antibiotic Potentiators Targeting SOS Induction
    Timothy Opperman; Fiscal Year: 2009
    ..goal of this STTR proposal is to discover and develop drugs that are potentiators of clinically relevant fluoroquinolones by specifically inhibiting induction of the SOS response...
  30. Mechanisms of adverse host responses to antibiotics
    Michael Court; Fiscal Year: 2006
    ..This proposal focuses on the fluoroquinolones, particularly ciprofloxacin, which was the primary antibiotic used for anthrax post-exposure prophylaxis, and ..
  31. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy R Sterling; Fiscal Year: 2010
    b>Fluoroquinolones;particularly later-generation agents such as gatifloxacin and moxifloxacin, have excellent in vitro and in vivo activity against Mycobacteriumtuberculosis...
  32. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..that such a toxin is likely produced by an endosymbiotic bacteria rather than the fungus itself, and that fluoroquinolones targeting those endosymbiotic bacteria may prove efficacious in treating mucormycosis...
  33. Uptake of Fluoroquinolones and Tetracyclines by Gingiva
    John Walters; Fiscal Year: 2003
    ..b>Fluoroquinolones and tetracyclines are very useful because they are cell-permeant and have favorable activity...
  34. Treatment Outcomes for Patients with Extensively Drug Resistant Tuberculosis
    MAX O DONNELL; Fiscal Year: 2009
    ..TB), extensively drug resistant tuberculosis (XDR-TB) is defined as resistance to Isoniazid, rifampin, fluoroquinolones and one of three injectable second-line anti-TB agents...
  35. Quinolone Action During Mycobacterial Growth Arrest
    Karl Drlica; Fiscal Year: 2006
    ..Recent work with Escherichia coli has established the existence of a minor pathway of killing by fluoroquinolones that may bypass the negative effect of growth arrest...
  36. DNA GYRASE AND QUINOLONE RESISTANCE IN TUBERCULOSIS
    Karl Drlica; Fiscal Year: 2007
    ..Previous work showed that structure modifications at the C-8 position of fluoroquinolones increase antibacterial activity, particularly with fluoroquinolone-resistant mutants...
  37. INHIBITORS OF FLUOROQUINOLONE EFFLUX IN GRAM + PATHOGENS
    PENELOPE MARKHAM; Fiscal Year: 1999
    ..of fluoroquinolone therapy by both increasing the intrinsic susceptibility of these pathogens to fluoroquinolones and suppressing the emergence of drug-resistant variants...
  38. NOVEL APPROACHES TO ANTITUMOR DRUG DESIGN
    Laurence Hurley; Fiscal Year: 2004
    ..The specific objectives of the proposed research are to: 1. design and synthesize a series of fluoroquinolones with a dual mechanism of action so that different members of the series are optimized for one or the other of ..
  39. Resistant E.coli in Humans and Poultry
    James Johnson; Fiscal Year: 2005
    ..Does the research address a current and compelling problem of antimicrobial resistance that is of high public health importance and for which research is needed? [yes]. ..
  40. QUINOLONE RESISTANCE MECHANISMS IN STAPHYLOCOCCUS AUREUS
    David Hooper; Fiscal Year: 2007
    ..abstract_text> ..
  41. QUINOLONE RESISTANCE IN NOSOCOMIAL URINARY INFECTIONS
    Ebbing Lautenbach; Fiscal Year: 2004
    ....
  42. Quinolone resistant E coli in long term care facilities
    Ebbing Lautenbach; Fiscal Year: 2009
    ..abstract_text> ..
  43. Novel Application of Infection Control Strategies to Limit Transmission of ESBL'S
    Ebbing Lautenbach; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  44. Clinical Impact of Quinolone-Resistant E.coli carriage
    Ebbing Lautenbach; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  45. HAEMOPHILUS ANTIGEN REGULATION OF INFLAMMATION IN COPD
    Sanjay Sethi; Fiscal Year: 2003
    ..Identification of the integral bacterial and host components that contribute to immune-mediated inflammation in COPD will ultimately lead to novel therapeutic strategies to alter disease progression and improve outcome in COPD. ..
  46. Innate Immunity and exacerbations of COPD
    Sanjay Sethi; Fiscal Year: 2009
    ..The overall goal of this research is to identify specific aspects of the innate defense of the lung that determine the frequency of exacerbations in COPD that will serve as potential therapeutic targets to reduce exacerbations. ..
  47. Sensing Biowarfare Agents by Surface Enhanced Raman
    Donald Moir; Fiscal Year: 2005
    ....
  48. Pharmacodynamics in Antifungal Resistance
    David Andes; Fiscal Year: 2005
    ..The candidate's goal is to integrate knowledge of antifungal PD and the acquisition of approaches and skills in molecular biology through the completion of this grant. ..
  49. Structure Function Analysis of TB Pyrazinamidase
    Ying Zhang; Fiscal Year: 2005
    ..These studies will provide important information about mechanisms of PZA action and resistance and may help design new antituberculosis drugs. ..
  50. Type III Secretion Inhibitors for Anti-Infective Therapy
    Donald Moir; Fiscal Year: 2007
    ..aeruginosa TTSS; (3) Screen a diverse compound library to identify and validate TTSS inhibitors; and (4) Prioritize validated screening hits for in vitro potency, mechanism, spectrum, and selectivity. [unreadable] [unreadable]..
  51. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  52. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  53. DNA helicase and primase inhibitors for biodefense
    Donald Moir; Fiscal Year: 2006
    ..Finally, compounds will be tested for lack of toxicity to mammalian cells in culture, and lack of activity against eukaryotic polymerase alpha and helicase, resulting in a collection of validated hits. ..
  54. Plasmid-Mediated Quinolone Resistance
    George Jacoby; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  55. Discovery of B. pseudomallei Therapeutics for Biodefense
    Donald Moir; Fiscal Year: 2008
    ..pseudomallei targets. In Phase III, a potent, safe, orally active B. pseudomallei inhibitor will be advanced into IND enabling toxicology and safety pharmacology studies and file an IND. [unreadable] [unreadable] [unreadable]..
  56. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  57. Saccharide-Based Effectors of Cationic Antimicrobial Peptides
    Robert Kerns; Fiscal Year: 2007
    ..We are also investigating if certain types of therapeutic agents inhibit antibacterial activity of the antimicrobial peptides. [unreadable] [unreadable] [unreadable]..
  58. Strategies to Prevent COPD Exacerbation
    Fernando Martinez; Fiscal Year: 2007
    ..abstract_text> ..
  59. Aggressive Periodontitis and Formylpeptide Receptor SNPs
    John Walters; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  60. Development of a HTS system:topoisomerase targets (RMI)
    Yuk Ching Tse Dinh; Fiscal Year: 2004
    ..The screening system should also be applicable for targeting topoisomerases in pathogenic bacteria relevant for biodefense. ..
  61. BACTERIAL DNA HELICASES: TARGETS FOR NOVEL ANTIBIOTICS
    Marjorie Barnes; Fiscal Year: 2005
    ..In Phase II, we will characterize the mechanism of action of the validated hits in more detail and optimize the most promising of these structures utilizing a rational drug design approach to develop antibacterial lead compounds. ..
  62. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..In initial studies, spores will be given subcutaneosly. Efficacy parameters will be defined as above. Successful trials can lead to phase I studies in humans, and treatment studies in non-human primates. ..
  63. Duke University Center for Translational Research
    Richard Frothingham; Fiscal Year: 2006
    ....